Related Experiment Video
Updated: May 9, 2025

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Endothelial Function Biomarkers in Hypertension
Panayotis K Vlachakis1, Panagiotis Theofilis1, Efstathios Manios2
11st Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, Athens, 11527, Greece.
Insights
Hypertension (HTN) is a leading cause of death, driven by endothelial dysfunction. Biomarkers from blood and imaging can detect this dysfunction early, aiding diagnosis and treatment strategies for cardiovascular disease.
Area of Science:
- Cardiovascular Medicine
- Biomarker Research
- Hypertension Pathophysiology
Background:
- Hypertension (HTN) is a critical cardiovascular risk factor responsible for millions of deaths annually.
- The pathophysiology of HTN involves complex mechanisms, notably endothelial dysfunction characterized by imbalances in vasoactive substances and inflammation.
- Early detection of HTN and its complications is vital for effective management and prevention of long-term adverse outcomes.
Purpose of the Study:
- To explore the role of endothelial function biomarkers in the early detection and understanding of hypertension.
- To identify key blood- and imaging-based biomarkers indicative of endothelial dysfunction in HTN.
- To assess the potential of these biomarkers in guiding diagnosis and treatment strategies for hypertensive patients.
Main Methods:
- Review of existing literature on biomarkers associated with endothelial dysfunction in hypertension.
- Identification of blood-derived biomarkers such as nitric oxide (NO), asymmetric dimethylarginine (ADMA), matrix metalloproteinases (MMPs), VCAM-1, ICAM-1, and endothelial microparticles.
- Inclusion of imaging-based biomarkers like flow-mediated dilation (FMD) and coronary flow reserve (CFR).
Main Results:
- Endothelial dysfunction is a central feature of HTN, contributing to elevated blood pressure and vascular damage.
- Various blood and imaging biomarkers can effectively indicate inflammation, endothelial dysfunction, and vascular injury in HTN.
- These biomarkers, alongside blood pressure measurements, enhance early diagnosis and provide insights into disease mechanisms.
Conclusions:
- Biomarkers of endothelial function hold significant promise for the early detection and improved management of hypertension.
- Further large-scale, prospective studies are required to fully validate these biomarkers for widespread clinical application.
- The integration of biomarker analysis with BP monitoring can refine diagnostic accuracy and personalize treatment approaches for cardiovascular disease.
Abstract:
Hypertension (HTN) is a major cardiovascular risk factor, contributing to over 10.4 million deaths annually. HTN's pathophysiology involves complex mechanisms, including altered vascular resistance and hormonal regulation. Endothelial dysfunction, a hallmark of HTN, is characterized by reduced vasodilator production and increased vasoconstrictor and inflammatory cytokine generation, leading to elevated blood pressure (BP) and vascular damage. Early detection and intervention are crucial to prevent long-term complications. Identifying biomarkers of endothelial function in HTN can aid early disease detection and offer insights into underlying mechanisms. Blood sample-derived biomarkers include nitric oxide (NO), asymmetric dimethylarginine (ADMA), matrix metalloproteinases (MMPs), vascular cell adhesion molecule-1 (VCAM- 1), intercellular adhesion molecule-1 (ICAM-1), and endothelial microparticles. Imaging-based biomarkers such as flow-mediated dilation (FMD) and coronary flow reserve (CFR) are also significant. These biomarkers provide the means to identify inflammation, endothelial dysfunction, and vascular injury, enhancing disease pathogenesis understanding. Combined with accurate BP measurements, they contribute to early diagnosis and provide valuable insights that may inform treatment strategies. Baseline and sequential plasma biomarker measurements also indicate treatment efficacy. However, large-scale, prospective population studies are necessary to fully validate these biomarkers for clinical use.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hypertension and Regulation of Blood Pressure
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Hormonal Regulation
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...

